Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Prosensa Holding N.V.
Headquarters: Leiden, Netherlands
Website: N/A
Year Founded: 2002
Status: Acquired
BioCentury | Dec 10, 2022
Product Development
Dec. 9 Quick Takes: Trio of biotechs parlays data into follow-ons
Plus: Erasca adds pan-RAF inhibitor from Novartis, and updates from UCB, Ambrx, Pharvaris and more
BioCentury | May 11, 2021
Finance
Droia parlays cancer fund success into genetic disease-themed vehicle as Golumbeski joins as partner
Firm expands into genetic diseases with €220M fund
BioCentury | Jul 29, 2020
Finance
With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett
BioCentury | May 31, 2018
Emerging Company Profile
Oral route for HAE
Why Pharvaris believes its oral compound can stand out in the crowded HAE field
BioCentury | Jan 12, 2018
Product R&D
Avidity’s affinity for muscle
How Avidity is delivering oligo therapies outside the liver
BioCentury | Sep 28, 2017
Product R&D
Wave’s purity progress
Wave reveals how it makes its stereopure oligos
BioCentury | Mar 2, 2017
Finance
Speeding up DMD
CureDuchenne makes largest investment to speed CRISPR DMD therapy into clinic
BioCentury | May 16, 2016
Finance
Global ambitions
Why European biotechs should start courting U.S. capital now
Items per page:
1 - 10 of 94